Allarity Therapeutics Enters Settlement Agreement with Novartis
Allarity Therapeutics has reached a settlement agreement with Novartis regarding a $4.9 million liability plus interest.
Stocks · News reference
Allarity Therapeutics Schedules Q3 2026 Earnings Announcement
Allarity Therapeutics, Inc. is scheduled to release its financial results for the third quarter of 2026 on November 12, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Allarity Therapeutics, Inc. (ALLR)
Filed: 2026-11-02 AccNo: 0001213900-26-114682 Size: 261 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Allarity Therapeutics Terminates Common Stock Purchase Agreement with Tumim Stone Capital
Allarity Therapeutics has terminated its common stock purchase agreement with Tumim Stone Capital, effective October 28, 2026, and plans to seek alternative financing.
Allarity Therapeutics Terminates $6M Equity Purchase Agreement With Tumim Stone Capital To Pursue Alternative Financing; Says No Early Termination Penalty Is Payable
Allarity Therapeutics Secures First Commercial Contract for CLIA Laboratory Services
Allarity Therapeutics has entered into its first revenue-generating agreement for its newly launched CLIA-certified laboratory services, providing development and validation support to a European biotech firm.
Allarity Therapeutics Receives First Contract For Its Development, Validation And Related Laboratory Services From Undisclosed European Biotech Firm